Sign in
CompletedNo phase

Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab

Key facts

Who runs it
Daewoong Pharmaceutical Co. LTD.
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
10,067 people enrolled
Started
6 Jul 2022
Ended
8 Nov 2024
Type of study
Observational
Treatments tested
  • Fexuprazan
Record updated
24 January 2025

Who can take part

Age
19 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Adult aged 19 years to 75 years (on registration date)
  • Patient scheduled to administer Fexuclue tablet based on the medical judgment of investigator
  • Patient who agreed to participate in this observation study and signed Informed Consent Form

Who cannot take part

  • A person who participates in another clinical trial and is administering (applying) clinical trial drugs or clinical trial medical devices
  • A person who falls under the prohibition of administration according to the permission for Fexuclue Tablet; Patients with hypersensitivity to the components of Fexuclue tablet or Fexuclue tablet and a history thereof; Patients undergoing Atazanavir, Nelfinavir or Lilpivirin-containing preparations; Pregnant and lactating women; Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabortion
  • In addition to the above, a person who has determined that the researcher (the doctor in charge) is not suitable for participation in this observation study

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This observational study is a large-scale, prospective, and multi-institutional observational study.

Read full original descriptionShow less

Patients from 19 to 75 years of age, will take a self-assessment (PRO) during the study period before and after administration of Pexuclue tablet.

The group in the trial

  • Treatment group

    treated with Fexuclue Tablet 40mg

    Treatment: Fexuprazan

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multi-Center, Prospective, Observational Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab. in Patients With Erosive Gastroesophageal Reflux Disease
Record updated
24 January 2025
Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab (NCT05614752) – Frontlight Research